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Incorporating cost-effectiveness data in the priority-setting decisions is a distinguishing feature in the Swedish national guidelines. This differentiates the Swedish guidelines 
from its European and American counterparts. The broader 
perspective is aimed at facilitating explicit resource allocations 
and priority-setting in healthcare, all in accordance with the 
three guiding ethical principles stated in the Health and Medical 
Services Act.1 The guidelines consist of recommendations 
in the form of a priority-setting decisions produced by a 
Priority-Setting Group (PSG) and the work process involves 
appraising the evidence used as decision support (including 
cost-effectiveness). 
In our article “Use of cost-effectiveness data in priority-setting 
decisions: experiences from the national guidelines for heart 
diseases in Sweden” we expressed that “economic evidence 
should be viewed as part of the evidence-based knowledge 
“package.” It is not our intention to argue that healthcare 
priority-setting should be based solely on cost-effectiveness 
data. The use of cost-effectiveness data represents one of many 
factors that play a role in health policy decision-making.”2 
Despite the “success” of using cost-effectiveness data in 
decision-making as commented by Williams and Bryan3 and 
also being “a wonderful exception to this rule” as commented 
by Erntoft,4 it was well-observed that cost-effectiveness data 
was lacking as decision support in the majority of cases. The 
study design did not use quantitative approach, to explore the 
use of cost-effectiveness data in decision-making. Instead, 
we have given examples of situations when cost-effectiveness 
arguments impacted decisions taken and was used in the PSG 
deliberations. 
There is a need to recognise the contextual elements in 
decision-making, as Williams and Bryan put it, and highlight 
institutional factors and incentives to employ use of cost-
effectiveness analyses in decision-making.5 The linear and 
simplistic goal of arriving at collective agreement is presented 
as an ideal for how to work with evidence-based policy (EBP). 
The work on producing as well as implementing guidelines, is 
*Correspondence to: Nathalie Eckard, Email: nathalie.eckard@liu.se
Copyright: © 2015 by Kerman University of Medical Sciences
Citation: Eckard N, Janzon M, Levin LA. Including both costs and effects – 
the challenge of using cost-effectiveness data in national-level policy-making: a 
response to recent commentaries. Int J Health Policy Manag. 2015;4(8):565-566. 
doi:10.15171/ijhpm.2015.123
Received: 23 June 2015, Accepted: 3 July 2015, ePublished: 8 July 2015
not as easily achieved as is preferably framed in the idealistic 
rational policy-making model. In practice, all steps – when 
evidence is produced, when evidence-informed guidelines 
in the form of policy documents are produced and when 
these guidelines are interpreted and used in practice – involve 
negotiations and collective sense-making.1,6
Our case study of the national guidelines constitute national-
level policy decision-making. We are aware of the fact that, 
empirical research has shown that healthcare decision-
makers at the local level have not yet accepted the use of cost-
effectiveness evidence in their decision-making to the same 
extent as at the national level concerning pharmaceuticals.7 
One reason for this is that affordability is often a pressing 
issue at local level decision-making and outcomes are seldom 
viewed in relation to cost. At a national policy level in Sweden, 
a societal perspective including both costs and effects is often 
applied. Though, the commentary by Erntoft concludes that 
certain conditions need to be fulfilled to enable the use of cost-
effectiveness data in real life.4 These include lack of budget 
restriction, strategies to handle uncertainty, transparency, 
legitimising health economics through a health economist 
attending the PSG deliberations, and clear instructions (use 
of templates) and nicely fits the results of our study.
Cost-effectiveness data played an important role in cases of 
greater uncertainty and ambiguity. Economic arguments 
clearly became a part of the PSG deliberation when the group 
members had difficulty in reaching agreement. As observed 
by Youngkong,8 setting healthcare priorities is not likely to 
succeed without considering deliberative processes among 
concerned stakeholders, justifying their reasons to maintain 
authority in decision-making. The use of cost-effectiveness 
data may therefore be regarded as a format for moving the 
work process forward, avoiding blocks in discussion, and 
viewed as a “solution” to solve the task of making priority-
setting decisions. Using cost-effectiveness arguments was also 
used to structure the discussions and interestingly was not 
challenged to the same extent as clinical evidence. Economic 
arguments was used as a fine-tuning instrument and a 
counterweight for dichotomization. 
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